|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.285 SEK | -1.55% |
|
-9.52% | -30.06% |
| Mar. 26 | Transcript : Vivesto AB - Special Call | |
| Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Vivesto AB reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was SEK 1.02 million compared to SEK 26.19 million a year ago. Net loss was SEK 166.68 million compared to SEK 132.72 million a year ago.
Basic loss per share from continuing operations was SEK 0.34 compared to SEK 0.3 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -30.06% | 13.99M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
VIVESTO AB 
